{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Arnold SM"],"funding":["NCI NIH HHS"],"pagination":["252-259"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5514161"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["1(4)"],"pubmed_abstract":["<h4>Purpose</h4>Low-dose fractionated radiation therapy (LDFRT) induces effective cell killing through hyperradiation sensitivity and potentiates effects of chemotherapy. We report our second investigation of LDFRT as a potentiator of the chemotherapeutic effect of induction carboplatin and paclitaxel in locally advanced squamous cell cancer of the head and neck (SCCHN).<h4>Experimental design</h4>Two cycles of induction therapy were given every 21 days: paclitaxel (75 mg/m<sup>2</sup>) on days 1, 8, and 15; carboplatin (area under the curve 6) day 1; and LDFRT 50 cGy fractions (2 each on days 1, 2, 8, and 15). Objectives included primary site complete response rate; secondary included overall survival, progression-free survival (PFS), disease-specific survival, and toxicity.<h4>Results</h"],"journal":["Advances in radiation oncology"],"pubmed_title":["Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial."],"pmcid":["PMC5514161"],"funding_grant_id":["P30 CA177558"],"pubmed_authors":["Valentino J","Kudrimoti M","Gleason JF","Dressler EV","Silver NL","Arnold SM","Regine WF"],"additional_accession":[]},"is_claimable":false,"name":"Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial.","description":"<h4>Purpose</h4>Low-dose fractionated radiation therapy (LDFRT) induces effective cell killing through hyperradiation sensitivity and potentiates effects of chemotherapy. We report our second investigation of LDFRT as a potentiator of the chemotherapeutic effect of induction carboplatin and paclitaxel in locally advanced squamous cell cancer of the head and neck (SCCHN).<h4>Experimental design</h4>Two cycles of induction therapy were given every 21 days: paclitaxel (75 mg/m<sup>2</sup>) on days 1, 8, and 15; carboplatin (area under the curve 6) day 1; and LDFRT 50 cGy fractions (2 each on days 1, 2, 8, and 15). Objectives included primary site complete response rate; secondary included overall survival, progression-free survival (PFS), disease-specific survival, and toxicity.<h4>Results</h","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Oct-Dec","modification":"2025-04-05T11:21:36.127Z","creation":"2019-03-27T02:50:43Z"},"accession":"S-EPMC5514161","cross_references":{"pubmed":["28740895"],"doi":["10.1016/j.adro.2016.06.003"]}}